The Technical Analyst
Tenax Therapeutics Inc [TENX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Tenax Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.24% $3.70
America/New_York / 19 apr 2024 @ 10:06
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.24 mill |
| EPS: | -31.04 |
| P/E: | -0.120 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 1.958 mill |
| Avg Daily Volume: | 0.356 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.120 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.120 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.14 - 4.26 ( +/- 15.11%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-11 | Hoffman Lawrence R | Sell | 0 | Common Stock |
| 2022-09-21 | Rich Stuart | Buy | 1 909 585 | Common Stock |
| 2022-09-21 | Rich Stuart | Sell | 1 909 585 | Common Stock |
| 2022-08-11 | Doogan Declan | Sell | 567 871 | Common Stock |
| 2022-06-09 | Rich Stuart | Buy | 100 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 26.45 |
| Last 92 transactions |
| Buy: 35 341 052 | Sell: 26 670 670 |
Forecast:
11:45 - $3.61
Live Trading Signals (every 1 min)
Forecast
1: 10:15 - $3.70
Forecast 2: 11:05 - $3.66
Forecast 3: 11:45 - $3.61
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.70 (0.24% ) |
| Volume | 0.0039 mill |
| Avg. Vol. | 0.356 mill |
| % of Avg. Vol | 1.087 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TENX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.11 | N/A | Active |
|---|
TENX
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Latest Press Releases
2024-04-09 08:30:00 - Press Release
Tenax Therapeutics To Host Kol Event: “level Setting: The Scientific Rationale For Levosimendan As A Potential First Treatment For Ph-hfpef, And The Ongoing Phase 3 Level Study”
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (ph-hfpef) and the potential role for levosimendan in treating this prevalent, fatal disease
2024-03-28 08:30:00 - Press Release
Tenax Therapeutics Provides Business And Clinical Development Updates With Full Year 2023 Financial Results
Chapel hill, n.c., march 28, 2024 (globe newswire) -- tenax therapeutics, inc. (nasdaq: tenx), a phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced full year 2023 financial results, and provided clinical development and business updates.
2024-03-12 08:30:00 - Press Release
Tenax Therapeutics To Present At The 36th Annual Roth Conference
Chapel hill, n.c., march 12, 2024 (globe newswire) -- tenax therapeutics, inc. (nasdaq: tenx), a phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the 36th annual roth conference in dana point, california, from march 17-19, 2024. tenax's ceo, chris giordano, will provide an update on the company and the ongoing development of levosimendan, in a conference session investors can attend in person, or via webcast.
2024-02-29 09:00:00 - Press Release
Tenax Therapeutics Announces Oral Presentation Of Levosimendan For The Treatment Of Ph-hfpef At Tht 2024
Dr. sanjiv shah, a renowned, global expert in the treatment of hfpef and ph-hfpef, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (ph-hfpef)
2024-02-20 08:30:00 - Press Release
Tenax Therapeutics Announces Global License Amendment That Significantly Expands Rights To Levosimendan
Chapel hill, n.c., feb. 20, 2024 (globe newswire) -- tenax therapeutics, inc. (nasdaq: tenx), a phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced it has secured global development, commercial, and ip rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef).
Latest News
2024-03-12 08:30:00 - GlobeNewsWire
Tenax Therapeutics to Present at the 36th Annual Roth Conference
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024. Tenax's CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a conference session investors can attend in person, or via webcast.
2024-02-08 08:53:54 - InvestorPlace
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
Tenax Therapeutics (NASDAQ: TENX ) stock is falling hard on Thursday after the pharmaceutical company announced details for a public offering of its shares. That public offering has Tenax Therapeutics selling 1.6 million units.
2024-02-06 10:01:21 - Invezz
Biotech stock Tenax Therapeutics more than doubled on Tuesday
Tenax Therapeutic Inc (NASDAQ: TENX) opened nearly 150% up this morning after receiving approval for a patent application. Tenax Therapeutics stock rallies ahead of earnings The U.S. Patent and Trademark Office accepted its patent application for levosimendan – its candidate treatment for pulmonary hypertension in patients of heart failure.
2023-11-13 15:22:18 - InvestorPlace
Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?
Shares of pharmaceutical specialist Tenax Therapeutics (NASDAD: TENX ) are skyrocketing on Monday amid encouraging regulatory news. More specifically, with a focus on addressing cardiovascular and pulmonary diseases with high unmet medical need, Tenax has received clearance for its investigational new drug (IND) application for its pulmonary hypertension therapeutic.
2023-11-13 12:27:20 - Proactive Investors
Tenax Therapeutics shares soar after FDA clears IND for hypertension candidate NX-103
Shares of Tenax Therapeutics surged over 300% after it announced the US Food and Drug Administration has reviewed and cleared its Investigational New Drug (IND) application for its hypertension candidate, TNX-103. The specialty pharmaceutical company said the FDA's enables it to proceed with the first of two Phase 3 studies for TNX-103 (oral Levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
2023-08-25 07:20:36 - InvestorPlace
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
2023-05-31 11:16:41 - PennyStocks
5 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
2023-03-14 06:00:00 - PennyStocks
Penny Stocks Trading: Tips for Setting Realistic Investing Goals
Setting penny stocks investing goals? Use these 3 top tips The post Penny Stocks Trading: Tips for Setting Realistic Investing Goals appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-13 06:00:00 - PennyStocks
Analyzing Penny Stocks After a Market Crash, 3 Tips
Use these tips for analyzing penny stocks after a market crash The post Analyzing Penny Stocks After a Market Crash, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-02-02 07:52:50 - InvestorPlace
Why Is Tenax Therapeutics (TENX) Stock Up 149% Today?
Tenax Therapeutics (NASDAQ: TENX ) stock is rocketing higher on Thursday after getting an update on one of its patents. That includes a Notice of Allowance from the USPTO.